MedPath

KeyBioscience AG

🇨🇭Switzerland
Ownership
Private
Employees
-
Market Cap
-
Website

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Phase 2
Recruiting
Conditions
Osteoarthritis in the Knee
Obesity
Interventions
Drug: Placebo
First Posted Date
2025-02-19
Last Posted Date
2025-02-19
Lead Sponsor
KeyBioscience AG
Target Recruit Count
600
Registration Number
NCT06833749
Locations
🇨🇿

Pratia Brno, s.r.o, Brno, Czech Republic

🇨🇿

L.K.N. Artrocentrum, Hlučín, Czech Republic

🇨🇿

Medical Plus, s.r.o, Hradiště, Czech Republic

and more 17 locations

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Phase 1
Terminated
Conditions
Type II Diabetes Mellitus
Interventions
Drug: Daily injection of KBP/placebo for up to 28 days
First Posted Date
2019-04-08
Last Posted Date
2020-09-03
Lead Sponsor
KeyBioscience AG
Target Recruit Count
25
Registration Number
NCT03907202
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
First Posted Date
2017-07-26
Last Posted Date
2018-09-11
Lead Sponsor
KeyBioscience AG
Target Recruit Count
255
Registration Number
NCT03230786
Locations
🇨🇿

Vdoviak Miroslav MUDr. - Interní Ambulance, Karlovy Vary, Czechia

🇨🇿

General University Hospital, Prague 2, Czechia

🇨🇿

Institute for Clinical and experimental Medicine, Praha 4, Czechia

and more 25 locations
© Copyright 2025. All Rights Reserved by MedPath